Drug
Donepezil
Donepezil: highest development phase Post-Market, developed by Eisai, Merck. 6 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Eisai, Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Donepezil NCT00381381 | Post-Market | Alzheimer's Disease |
| Donepezil NCT02787746 | Post-Market | Alzheimer's Disease |
| Donepezil hydrochloride NCT00096473 | Phase 3 | Alzheimer's Disease |
| Donepezil NCT00006399 | Phase 2 | Alzheimer Disease |
| Donepezil NCT02064920 | Phase 2 | Alzheimer's Disease |
| donepezil NCT01023867 | Not Applicable | Alzheimer's Disease |
Latest
No recent events.
Follow Donepezil on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.